医学顾问/医学专员
百奥泰生物制药股份有限公司
- 公司规模:500-1000人
- 公司性质:合资
- 公司行业:制药/生物工程
职位信息
- 发布日期:2019-11-04
- 工作地点:广州-黄埔区
- 招聘人数:1人
- 工作经验:2年经验
- 学历要求:本科
- 职位月薪:7-35万/年
- 职位类别:医药学术推广 其他
职位描述
医学顾问/医学专员--风湿类生物制剂
主要职责:
1.提供医学支持和医学及产品相关知识培训;
2.医学文献查询,报告撰写;
3.临床医生/患者的医学咨询支持;
4.医学工具及推广材料制作;确保医学合规;
5.外部客户拜访与沟通,管理;
6.跨部门沟通与协调;
7.完成上级交办的其他任务;
任职资格:
1.临床医学相关专业本科或以上学历;有内科/风湿免疫科临床工作经验者优先;
2.2年或以上医药企业医学部工作经验,有风湿免疫领域工作经验优先;
3.书面和口头表达能力优秀,熟练进行中英文专业文献检索及阅读,主动性强、优秀的学习能力、沟通能力、创造性,良好的团队协作能力;
4.具备较强的抗压能力,能适应出差。
公司介绍
百奥泰生物制药股份有限公司(股票代码:688177)秉承“创新只为生命”的理念,致力于开发新一代创新药和生物类似药,用于治疗肿瘤、自身免疫性疾病、心血管疾病以及其它危及人类生命或健康的重大疾病。公司已推动五款候选药物进入后期临床试验,其中格乐立(阿达木单抗)已在中国获批用于治疗类风湿关节炎、强直性脊柱炎、银屑病、克罗恩病和葡萄膜炎。此外,公司另有多款主攻肿瘤和自身免疫性疾病的候选药物处于不同的临床开发阶段。公司始终以患者的福祉作为首要核心价值,通过创新研发为患者提供安全、有效、可负担的优质药物,以满足亟待解决的治疗需求。欲了解更多信息,请访问公司官网或关注我们的微信公众号“百奥泰”。
Bio-Thera?Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to?Humira?(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,?Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
Bio-Thera?Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to?Humira?(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,?Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
联系方式
- Email:bd@bio-thera.com
- 公司地址:广州科学城开源大道11号科技企业加速器A6幢5楼 (邮编:510530)